SIGA Technologies Inc. in New York, New York said today it received notice that the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), intends to award a contract for the company’s smallpox antiviral for the strategic national stockpile. SIGA says a protest from another company in the competition for the award first needs to be resolved before the award can take place.
SIGA Technologies develops products for the prevention and treatment of infectious diseases, with an emphasis on products for biological warfare defense. SIGA says its technology applies viral and bacterial genomics and computational modeling.
Under the contract, BARDA calls for SIGA to deliver 1.7 million courses of its smallpox drug. The base contract, once awarded, is expected to generate revenues of about $500 million, with the entire contract, if all options are exercised, generating revenues of up to $2.8 billion.
The company says Chimerix Inc. has filed a small business size protest against SIGA after receiving pre-award notice from HHS that Chimerix was an unsuccessful bidder. HHS designated the proposed contract as a small business set-aside at the time of the original solicitation in March 2009. SIGA says it intends to respond to Chimerix’s protest.